PRLD
USDPrelude Therapeutics Incorporated Common Stock
Real-time Price
Price Chart
Key Metrics
Market Metrics
Open
$1.190
High
$1.280
Low
$1.173
Volume
1.13M
Company Fundamentals
Market Cap
71.5M
Industry
Biotechnology
Country
United States
Trading Stats
Avg Volume
1.27M
Exchange
NMS
Currency
USD
52-Week Range
Related News
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with
Prelude Therapeutics Announces Strategic Business Update
Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
WILMINGTON, Del., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude" or the "Company"), a clinical-stage precision oncology company, today announced the publication of two
Related Stocks
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.